BMS makes further investment in innate immunity

After securing rights to a compound developed by Innate Pharma SA in 2011, Bristol-Myers Squibb Company (BMS) has expanded its investment in innate immunity with the purchase of IFM Therapeutics Inc of Boston, Massachusetts.

Full text available to subscribers only. Click here for information on subscribing to MedNous.


United States